Access cutting-edge hemophilia b treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.
Access hemophilia b specialists in Minneapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hemophilia b treatment provided free
The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of a single intravenous (IV) dose of BE-101 in adults with moderately severe or severe Hemophilia B. Once infused, BE-101 is designed to engraft and continuously secrete FIX into the circulation to restore clinically meaningful levels of active FIX. BE-101 is an autologous (person's own cells) B Cell Medicine (BCM) which uses CRISPR/Cas9 gene
Sponsor: Be Biopharma
Check if you qualify for this hemophilia b clinical trial in Minneapolis, MN
If you're searching for hemophilia b treatment options in Minneapolis, MN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hemophilia b specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.